Invivyd reports Q2 2024 net product revenue of $2.3M, expects 2024 revenue of $150-200M

Invivyd, Inc.

2024-Q2 EPS reported -$0.77 revenue$2,264,000

PEMGARDA launched commercially in Q2 2024 with $2.3M net product revenue; early Q3 commercial acceleration noted.
Cash and cash equivalents were $147.9M as of June 30, 2024; projected year-end cash at least $75M.
EUA amendment request submitted to FDA for PEMGARDA for treatment of mild-to-moderate COVID-19 in immunocompromised patients.
Next-generation molecule VYD2311 first-in-human trial dosing scheduled to begin late August 2024.
Tim Lee joined as Chief Commercial Officer; board expanded with Srishti Gupta and Kevin F. McLaughlin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.